Soiken Holdings Inc. (TYO:2385)

Market Cap	6.43B +105.0%
Revenue (ttm)	4.87B -10.2%
Net Income	163.00M
EPS	6.23
Shares Out	26.16M
PE Ratio	39.48
Forward PE	n/a
Dividend	5.00 (1.95%)
Ex-Dividend Date	n/a

Volume	192,900
Average Volume	147,225
Open	255.00
Previous Close	257.00
Day's Range	245.00 - 255.00
52-Week Range	116.00 - 325.00
Beta	-0.13
RSI	49.56
Earnings Date	Feb 12, 2026

About Soiken Holdings

Soiken Holdings Inc. engages in the development of biomarkers in Japan. It is involved in the development and sale of cosmetics and dietary supplements comprising imidapeptides; licensing and development of biomarker technology; provision of marketing research and post-marketing surveys for dietary supplements; and research, development, and sale of functional materials, such as lactoferrin, as well as pharmaceutical products from ascochlorin derivatives. The company also provides clinical evaluation tests for foodstuffs using biomarker technol...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 81
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 2385

Financial Performance

In fiscal year 2025, Soiken Holdings's revenue was 4.85 billion, a decrease of -6.01% compared to the previous year's 5.16 billion. Losses were -210.00 million, -68.28% less than in 2024.